Published on November 30, 2009 at 7:54 AM
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.
Results from the completed phase 2 clinical trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentation. An update from the ongoing phase 1 trial with blinatumomab in patients with non-Hodgkin's lymphoma (NHL) will be presented in a poster.
(1) Topp et al, (2009) Report of a phase II trial of single-agent BiTE antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL): 51st ASH meeting (2009), abstract number 840; oral presentation on December 8 in rooms 220-222 at 8:45 AM.
(2) Nagorsen, et al. (2009) Confirmation of safety, efficacy and response duration in non-Hodgkin lymphoma patients treated with 60 micrograms/squaremeter per day of BiTE antibody blinatumomab. 51st AST meeting (2009), abstract number 2723; to be presented in poster presentation on December 6, 2009, 6:00 PM.
For more information and for complete abstracts, please visit http://ash.confex.com/ash/2009/webprogram/start.html
SOURCE Micromet, Inc.